March 2021-Hukui Bio joined as a member of Johnson and Johnson's JLabs Resource Hub and it is the only CDMO service provider for medtech innovations in the ecosystem.
The growth rate of contract development and manufacturing organization (CDMO) market is faster than the overall medical device market.
As the electronic medical devices market grows, the specialization of the products creates greater demand for outsourcing development and manufacturing services, the CDMO is thus more needed.
1/16/2021-Hukui Bio has announced that it has raised US$5.5 million in Series C funding, led by Yellowstone Holding AG from Switzerland, totaling US$11.8M funding to date.
HuKui Bio will collaborate with venture capital funds in the Bay area, in addition to the biomedical innovation clusters and accelerators in Europe and the US. The New Business Department and the US subsidiary in the Bay area were founded at the beginning of 2021, with the onboarding of Dr IC Jan as the Chief Strategy Officer.
Hukui Bio CEO, Michael Kuo said, “Because of the U.S.-China trade war and epidemic COVID-19, the global medical device demand and supply will be overwhelmed changed.”
After obtaining investment from European private equity fund- YELLOWSTONE at the end of last year, HukuiBio expands the business to worldwide medical device design, registration and manufacturing service.
In 2016, Hukui has established a factory in Beibei District, Chongqing. Its factory area is 4,300 square meters.
The Chongqing factory is equipped with electrical safety inspection equipment for active medical devices and has electrical safety inspection and testing capacity so as to effectively guarantee the safety and quality of products.
A clean production workshop of Class 100,000 is GB 50457 and YY0033 compliant to produce IVD products, sterile medical devices and implantable devices.
Add a footnote if this applies to your business